CT:IN InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, pulmonary disease, neurodegenerative, and oncology disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-755; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol INM.
This company has cross-listed shares that trade in the U.S. as the symbol INM.
4.19 CAD
As of 05/07/2021
Security Information
Category1: Global Equity
Category2: Common stocks
Category3: Developed markets ex-US
GICS sector: Health Care
Industry: Biotechnology
Index country: Canada
Country of incorporation: Canada
IPO date: 01/01/1900
Stock exchange: Toronto Stock Exchange
Exchange country: Canada
Market cap: 33,732,476 CAD
Current dividend yield: 0.00%
Sedol: